2025年1至6月份，ST香雪的营业收入构成为：中药材占比64.87%，医药制造占比22.53%，其它占比 20.22%，医药流通占比4.27%，医疗器械占比1.18%。 每经AI快讯，ST香雪（SZ 300147，收盘价：9.6元）11月28日晚间发布公告称，公司第九届第三十二次 董事会会议于2025年11月28日在公司本部会议室以现场结合通讯方式召开。会议审议了《关于不再设立 监事会并废止 <监事会议事规则> 的议案》等文件。 每经头条（nbdtoutiao）——已有75人遇难，1名死者为消防员，还有10名消防员受伤！记者现场直击香 港大埔火灾：燃烧的宏福苑，五级大火的五个谜团 （记者 王晓波） 截至发稿，ST香雪市值为63亿元。 ...

Core Viewpoint - ST Xiangxue announced the convening of its 31st meeting of the 9th board of directors on October 27, 2025, to review the full report for the third quarter of 2025 [1] Company Summary - For the first half of 2025, ST Xiangxue's revenue composition is as follows: Traditional Chinese medicine accounts for 64.87%, pharmaceutical manufacturing for 22.53%, other sectors for 20.22%, pharmaceutical distribution for 4.27%, and medical devices for 1.18% [1] - As of the report, ST Xiangxue has a market capitalization of 6.8 billion yuan [1]